Table 4 Microbiologic Response for Common Respiratory Pathogens at Test-of-Cure Visit in the ME Population
From: Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
| Â | Tigecycline | Levofloxacin | ||||
|---|---|---|---|---|---|---|
Isolate | n/N | % | (95% CI) | n/N | % | (95% CI) |
Streptococcus pneumoniae | 46/50 | 92.0 | (80.8, 97.8) | 32/36 | 88.9 | (73.9, 96.9) |
Penicillin-intermediate S. pneumoniae | 3/3 | 100 | (29.2,100) | 5/5 | 100 | (47.8, 100) |
Penicillin-resistant S. pneumoniae | 2/2 | 100 | (15.8, 100) | 3/3 | 100 | (29.2, 100) |
Haemophilus influenzae | 8/11 | 72.7 | (39.0, 94.0) | 6/7 | 85.7 | (42.1, 99.6) |
Haemophilus parainfluenzae | 5/5 | 100 | (47.8, 100) | 9/9 | 100 | (66.4, 100) |
Klebsiella pneumoniae | 4/4 | 100 | (39.8, 100) | 7/7 | 100 | (59.0, 100) |
Staphylococcus aureus (all non-MRSA) | 7/9 | 77.8 | (40.0, 97.2) | 6/6 | 100 | (54.1, 100) |
Chlamydia pneumoniae | 5/5 | 100 | (47.8, 100) | 11/11 | 100 | (71.5, 100) |
Mycoplasma pneumoniae | 24/25 | 96.0 | (79.6, 99.9) | 22/24 | 91.7 | (73.0, 99.0) |
Legionella pneumophila | 3/3 | 100 | (29.2, 100) | 5/5 | 100 | (47.8, 100) |